187 related articles for article (PubMed ID: 22563779)
1. Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I.
Czaja AJ
Inflamm Allergy Drug Targets; 2012 Oct; 11(5):337-50. PubMed ID: 22563779
[TBL] [Abstract][Full Text] [Related]
2. Drug choices in autoimmune hepatitis: part B--Nonsteroids.
Czaja AJ
Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):617-35. PubMed ID: 23061712
[TBL] [Abstract][Full Text] [Related]
3. Current and prospective pharmacotherapy for autoimmune hepatitis.
Czaja AJ
Expert Opin Pharmacother; 2014 Aug; 15(12):1715-36. PubMed ID: 24961409
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune hepatitis: focusing on treatments other than steroids.
Czaja AJ
Can J Gastroenterol; 2012 Sep; 26(9):615-20. PubMed ID: 22993733
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies in autoimmune hepatitis.
Czaja AJ
Clin Liver Dis; 2002 Aug; 6(3):799-824. PubMed ID: 12362582
[TBL] [Abstract][Full Text] [Related]
6. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine.
de Boer NK; van Nieuwkerk CM; Aparicio Pages MN; de Boer SY; Derijks LJ; Mulder CJ
Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):457-61. PubMed ID: 15756101
[TBL] [Abstract][Full Text] [Related]
7. Evolving new therapies of autoimmune hepatitis.
Vierling JM; Flores PA
Clin Liver Dis; 2002 Aug; 6(3):825-50, ix. PubMed ID: 12362583
[TBL] [Abstract][Full Text] [Related]
8. The treatment of autoimmune hepatitis.
Malnick S; Duek G; Melzer E; Basevitz A
Curr Clin Pharmacol; 2012 Nov; 7(4):318-27. PubMed ID: 22794160
[TBL] [Abstract][Full Text] [Related]
9. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
Czaja AJ; Carpenter HA
J Clin Gastroenterol; 2005 Oct; 39(9):819-25. PubMed ID: 16145346
[TBL] [Abstract][Full Text] [Related]
10. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM
Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421
[TBL] [Abstract][Full Text] [Related]
11. Use of immunomodulary agents is difficult in treating autoimmune hepatitis patients.
Gordon FD; Simpson M
J Clin Gastroenterol; 2004 Oct; 38(9):729-30. PubMed ID: 15365394
[No Abstract] [Full Text] [Related]
12. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
[TBL] [Abstract][Full Text] [Related]
14. Expert clinical management of autoimmune hepatitis in the real world.
Liberal R; de Boer YS; Andrade RJ; Bouma G; Dalekos GN; Floreani A; Gleeson D; Hirschfield GM; Invernizzi P; Lenzi M; Lohse AW; Macedo G; Milkiewicz P; Terziroli B; van Hoek B; Vierling JM; Heneghan MA;
Aliment Pharmacol Ther; 2017 Mar; 45(5):723-732. PubMed ID: 28004405
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.
Than NN; Wiegard C; Weiler-Normann C; Füssel K; Mann J; Hodson J; Hirschfield GM; Lohse AW; Adams DH; Schramm C; Oo YH
Scand J Gastroenterol; 2016 Mar; 51(3):329-36. PubMed ID: 26458216
[TBL] [Abstract][Full Text] [Related]
16. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.
Baven-Pronk AM; Coenraad MJ; van Buuren HR; de Man RA; van Erpecum KJ; Lamers MM; Drenth JP; van den Berg AP; Beuers UH; den Ouden J; Koek GH; van Nieuwkerk CM; Bouma G; Brouwer JT; van Hoek B
Aliment Pharmacol Ther; 2011 Aug; 34(3):335-43. PubMed ID: 21668459
[TBL] [Abstract][Full Text] [Related]
17. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis.
Brunt EM; Di Bisceglie AM
Hum Pathol; 2004 Apr; 35(4):509-12. PubMed ID: 15116334
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Autoimmune Hepatitis.
Goel A; Kwo P
Clin Liver Dis; 2024 Feb; 28(1):51-61. PubMed ID: 37945162
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
De Lemos-Bonotto M; Valle-Tovo C; Costabeber AM; Mattos AA; Azeredo-da-Silva ALF
Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):212-216. PubMed ID: 29227329
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: a retrospective and prospective cohort study.
Ludz C; Stirnimann G; Semela D; Mertens J; Kremer AE; Filipowicz Sinnreich M; Sokollik C; Bernsmeier C; Bresson-Hadni S; McLin V; Rock N; Braegger C; Posovszky C; Müller P; Cremer M; De Gottardi A; Galante A; Furlano R; Righini-Grunder F; Becker B; Böhm S; Heyland K; Nydegger A; Limoni C; Vergani D; Mieli-Vergani G; Di Bartolomeo C; Cerny A; Terziroli Beretta-Piccoli B
Swiss Med Wkly; 2023 Aug; 153():40102. PubMed ID: 37769636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
